Fesharaki will be in charge of Lupin’s global R&D operations spanning branded, generic, and speciality products
Lupin announced the appointment of Shahin Fesharaki as Global Chief Scientific Officer. Fesharaki will be in charge of Lupin’s global R&D operations spanning branded, generic, and speciality products.
Fesharaki has approximately 30 years of expertise in drug development with prominent global pharmaceutical firms, most recently serving as Hikma Pharmaceuticals’ Chief Scientific Officer and Global Head of R&D. Fesharaki formerly held roles of increasing responsibility in Teva, Allergan/Actavis, Watson Pharmaceuticals, and Apotex.
“We are delighted to welcome Shahin to our leadership team,” stated Vinita Gupta, CEO and Nilesh Gupta, MD, Lupin, in response to the appointment. “Shahin’s remarkable track record of delivering brands and generics in developed and emerging countries will be invaluable as we accelerate our transition into complicated generics and specialities while driving growth in all of our main markets.”
Fesharaki has considerable development expertise in both generic and branded medications, spanning several technologies and dosage forms.
